智飛生物(300122.SZ):四價流腦結合疫苗申請生產註冊獲得受理
格隆匯5月30日丨智飛生物(300122.SZ)公佈,公司於近日獲悉,由全資子公司北京智飛綠竹生物製藥有限公司(以下簡稱“智飛綠竹”)研發的ACYW135羣腦膜炎球菌多糖結合疫苗(以下簡稱“四價流腦結合疫苗”)申請生產註冊獲得國家藥品監督管理局出具的《受理通知書》(受理號:CXSS2500056)。
流行性腦脊髓膜炎是由腦膜炎奈瑟菌引起的急性化膿性腦膜炎,具有起病急、進展快、傳染性強、病死率高、致殘率高等特點。智飛綠竹研發的四價流腦結合疫苗為預防用生物製品,可以預防由A、C、Y、W135羣腦膜炎球菌引起的流行性腦脊髓膜炎。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.